IGI 10% (TAK-339)

A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation AntigenxCD3-Directed Bispecific Antibody Therapy

Near Add Your Location

Sorting 8 by

Chao Family Comprehensive Cancer Center
University of California, Irvine
Orange, CA
  • Not yet accepting
University of Maryland Medical Center
Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, MD
  • Not yet accepting
Henry Ford Hospital
Detroit, MI
  • Not yet accepting
Alvin J. Siteman Cancer Center
Washington University Medical Campus
St. Louis, MO
  • Not yet accepting
East Carolina University Vidant Cancer Care
Eddie and Jo Allison Smith Tower
Greenville, NC
  • Not yet accepting
Cleveland Clinic - Taussig Cancer Center
Taussig Cancer Institute
Cleveland, OH
  • Not yet accepting

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.